Neoadjuvant vs Adjuvant Immune Checkpoint Blockade in the Treatment of Clinical Stage III Melanoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Neoadjuvant Versus Adjuvant Immune Checkpoint Blockade in the Treatment of Clinical Stage III Melanoma
Ann. Surg. Oncol 2020 Jan 02;[EPub Ahead of Print], Y Song, RJ Straker, X Xu, DE Elder, PA Gimotty, AC Huang, TC Mitchell, RK Amaravadi, LM Schuchter, GC KarakousisFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.